Reflecting On A Day Of Discussions Surrounding The Important Student Role From Invention To Commercialization

On March 22, 2013, IP Osgoode and the Canadian Intellectual Property Office (CIPO) co-hosted a conference examining the role of student researchers in commercializing intellectual property. Inspired by her SSHRC-funded research, IP Osgoode's Professor Giuseppina D’Agostino, the conference chair, skillfully orchestrated an impressive line-up of guest speakers and panellists representing the full spectrum of key stakeholders […]

The Teva Experience: A Semester in Osgoode's IP Intensive Program

As part of Osgoode’s Intellectual Property Law Intensive Program, I had the opportunity to spend ten weeks at Teva Canada working with in-house counsel. Teva Canada is one of Canada’s largest generic pharmaceutical companies that also has a brand division focusing on the development of innovative products in several therapeutic areas.

Subsequent Entry Biologic Litigation Set to Take Off in Canada

The Canadian pharmaceutical industry is entering a new era as Subsequent Entry Biologic (SEB) litigation begins to emerge in the Canadian pharmaceutical landscape. Biologic drugs are derived through the metabolic activity of living organisms and tend to be significantly more variable and structurally complex then chemically synthesized drugs.

Canada’s Top Court Gives Canadians Something to Get Excited About, Generic Viagra!

On November 8, 2012 the Supreme Court of Canada (SCC) released its eagerly anticipated decision in the “Viagra Appeal”. In a unanimous decision written by Justice LeBel, the SCC found the patent at issue invalid for insufficient disclosure. This decision marks the end of a lengthy legal battle between Teva and Pfizer over the validity […]

Disclosure Front and Centre as Pfizer Prepares to Defend Viagra in Supreme Court of Canada

This Wednesday, April 18, Pfizer will defend the patent protecting the little blue pill that has changed the lives of men and women around the world.  The pill is of course Viagra and the assailant is Teva, a generic pharmaceutical company.  Teva applied for a Notice of Compliance in order to market a generic version […]

Should Canada Strengthen IP Protection for Pharmaceutical Products? The European Union Thinks So...

The Canadian government and European Union (EU) are currently negotiating a Comprehensive Economic and Trade Agreement (CETA).  A key issue has been ensuring that Canadian intellectual property rights for pharmaceutical products are brought in line with EU standards.  It appears that the EU believes Canada’s legal regime regulating the approval of drugs does not provide […]

Warning: Patent Troll Seeks To Stamp Out Amazon's (Kindle) Fire

Sean Jackson is a JD candidate at Osgoode Hall Law School, and is currently enrolled in Professor Mgbeoji’s Patents class, in Fall 2011. As part of the course requirements, students are asked to write a blog on a topic of their choice. An ugly patent troll has reared its head again, this time targeting Amazon.  With […]

Canada, The Land of Hockey, Roll Up The Rim To Win and Pirates

Sean Jackson is a first year JD candidate at Osgoode Hall Law School and currently enrolled in the course Law & Social Change: Law & Music, in Winter 2011. As part of the course requirements, students are asked to write a blog on a topic of their choice. In the International Intellectual Property Alliance’s (IIPA) 2011 Special […]